Gregg Sherman, MD
Chief Medical Officer, NACE
Kilbride Associates Healthcare Communications
San Francisco, CA
Robert S. Busch, MD, FACE
Director of Clinical Research
Albany Medical Faculty: Community Endocrine Group
Richard S. Beaser, MD
Senior Staff Physician,
Medical Director of Professional Education
Joslin Diabetes Center
Associate Clinical Professor of Medicine
Harvard Medical School
Mark Stolar, MD
Associate Professor of Clinical Medicine
Feinberg School of Medicine
Richard Pratley, MD
Senior Investigator and Diabetes Program Head
Translational Research Institute for Metabolism and Diabetes
Research and Education Director, Florida Hospital Diabetes Institute
Jeff Unger, MD, ABFM, FACE
Director, Unger Primary Care Medical Group
Rancho Cucamonga, CA
||GLP-1 Receptor Agonists: New Insights and New Strategies for Successful: Long-Term Diabetes Management
||Jul 27 2017
||Jul 26 2018
||Primary Care Medicine
||Primary Care Providers
||1.0 AMA PRA Category I Credit(s)
1.0 AANP Contact hour(s) which includes 1.0 pharmacology hour(s)
| (Chrome not supported at this time)
Welcome to the National Association for Continuing Education webcast from the NACE Emerging Challenges in Primary Care 2017 conference.
Due to the progressive nature of T2DM, oral drugs alone are often insufficient for glycemic control, and most patients eventually need insulin therapy to reach/maintain glycemic targets. However, several clinician and patient barriers, including fears of hypoglycemia and weight gain, limit the use of insulin in practice. The glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may be alternatives to insulin in certain patients. The efficacy and benefits of these agents have been clearly demonstrated in clinical studies, but in practice, clinicians may have gaps in perception and knowledge of these and other T2DM therapies. This webcast, from the NACE Emerging Challenges in Primary Care 2017 conference, addresses these issues and provides strategies on how to incorporate GLP-1 RAs into practice. This webcast was recorded live and is being used with the permission of the presenters.
After completing this program participants should be able to:
- Discuss the role of postprandial hyperglycemia in the pathogenesis of diabetic complications.
- Incorporate GLP-1 RA therapy into practice to reduce post-prandial hyperglycemia and decrease glycemic variability.
- Compare GLP-1 RAs for glycemic efficacy and differential impact on postprandial glycemic control.
- Discuss various GLP-1 RA combination strategies with, or as a possible alternative to, basal insulin in the diabetic patient not at glycemic target.
How To Obtain Your CME Certificate 1. Register for the course at www.naceonline.com.
2. View the content.
3. Complete and submit the post-test and evaluation.
4. A minimum passing score of 80% must be earned on the post-test in order to complete the CME
5. Print your CME certificate.
National Association for Continuing Education
|Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The National Association for Continuing Education designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.
National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.0 contact hour of continuing education(which includes 1.0 pharmacology hour).
Policy on Faculty and Provider Disclosure: It is the policy of the National Association for Continuing Education to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. Faculty disclosures are provided below.
Robert S. Busch, MD, FACE serves as a speaker for Astra Zeneca, Eli Lilly, Boehringer Ingelheim, Novo Nordisk, and Shire. Dr. Busch also serves as a researcher for Astra Zeneca, Novo Nordisk, Janssen, and Amgen.
Richard S. Beaser, MD has no financial relationships to disclose.
Mark Stolar, MD serves as a speaker/advisory board member for Astra Zeneca.
Richard Pratley, MD serves as a speaker/consultant for AstraZeneca. Dr. Pratley also serves as a consultant for Boehringer-Ingelheim, GlaxoSmithKline, Hanmi Pharmaceutical Co., Ltd., Janssen Pharmaceuticals, Inc., and Ligand Pharmaceuticals, Inc. Additionally, Dr. Pratley performs research under contract for Lexicon Pharmaceuticals, Sanofi-Aventis US, LLC, Lilly, Merck, and Takeda. Dr. Pratley performs research, is a speaker and consultant for Novo Nordisk. All honoraria and fees are directed to a non-profit. Dr. Pratley does not receive any direct compensation for these activities.
Jeff Unger, MD, ABFM, FACE serves on the advisory board for Abbott, Novo Nordisk, Janssen, and Intarcia.
Gregg Sherman, MD, Course Director, has no relationships to disclose.
Josh Kilbridge, Medical Writer, has no relationships to disclose.
Harvey C. Parker, Ph.D., Activity Planning Committee, has no relationships to disclose.
Michelle Frisch, MPH, Activity Planning Committee, has no relationships to disclose.
Alan Goodstat, LCSW, Activity Planning Committee, has no relationships to disclose.
Cheryl C. Kay, Activity Planning Committee, has no relationships to disclose.
This activity is supported by an educational grant from Lilly.